DUBLIN, July 19, 2018 /PRNewswire/ -- Alkermes plc
(Nasdaq: ALKS) will host a conference call and webcast presentation
at 8:30 a.m. ET (1:30 p.m. BST) on Thursday, July 26, 2018, to discuss the company's
second quarter 2018 financial results. Management will also provide
an update on the company.
The webcast player and accompanying slides may be accessed on
the Investors section of Alkermes' website at www.alkermes.com. The
conference call may be accessed by dialing +1 888 424 8151 for U.S.
callers and +1 847 585 4422 for international callers. The
conference call ID number is 6037988.
A replay of the conference call will be available from
11:00 a.m. ET (4:00 p.m. BST) on Thursday, July 26, 2018, through 5:00 p.m. ET (10:00 p.m.
BST) on Thursday, Aug. 2,
2018, and may be accessed by visiting Alkermes' website or
by dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for
international callers. The replay access code is 6037988.
About Alkermes plc
Alkermes plc is a fully
integrated, global biopharmaceutical company developing innovative
medicines for the treatment of central nervous system (CNS)
diseases. The company has a diversified commercial product
portfolio and a substantial clinical pipeline of product candidates
for chronic diseases that include schizophrenia, depression,
addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D
center in Waltham, Massachusetts;
a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in
Wilmington, Ohio. For more
information, please visit Alkermes' website
at www.alkermes.com.
Alkermes Contact:
Sandra Coombs
Investor Relations
+1 781 609 6377
Logo -
https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg